POR FESR 2014-2020, Asse I, Azione 3.4.1. – Avviso Large 2021 – Regione Umbria
Feb 21, 2023
“Farmaci, i Successi del Made in Italy” Tes Pharma in "Otto e Mezzo" of La7
Dec 2, 2022
TES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with Severe Alcohol-Associated Hepatitis
Nov 8, 2022
X-ray Structure of Human ACMSD with TES-1025
Apr 8, 2022
Prof. Andrea Alimonti Visit Tes Pharma
Mar 18, 2022
Prof. Roberto Pellicciari Recipient of the EFMC Honorary Fellow Award.
Aug 18, 2021
POR FESR 2014-2020, Asse I, Azione 1.1.1. – Avviso Ricerca 2020 – Regione Umbria
Jul 15, 2021
POR FESR 2014-2020. Asse I Azione 1.1.1. – Avviso Ricerca 2018 – Regione Umbria
May 4, 2020
Mitochondrial Dysfunction is a Key Driver of Acute Kidney Injury Pathophysiology
Dec 18, 2018
Targeting NAD+ Synthesis via inhibition of ACMSD to prevent NAFLD and AKI
Nov 28, 2018
De novo NAD+ synthesis enhances mitochondrial function and improves health
Oct 25, 2018
POR FESR 2014-2020 Regione Umbria
Mar 22, 2018
α-Amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) Inhibitors as Novel Modulators of NAD+ Biosynthesis
Jan 29, 2018